<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170896</url>
  </required_header>
  <id_info>
    <org_study_id>1160.31</org_study_id>
    <nct_id>NCT02170896</nct_id>
  </id_info>
  <brief_title>Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects</brief_title>
  <official_title>Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each
      administered as four experimental capsule formulations relative to drinking solution with and
      without coadministration of 40 mg pantoprazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ae 0-12h: amount of drug (total BIBR 953 ZW) excreted into urine during all individual dosing intervals</measure>
    <time_frame>up to 3 days after each administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration time course at steady state (AUCss)</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>up to 40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax,ss)</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum plasma concentration occurs after dosing during steady state (tmax,ss)</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8 and 12 hours after study drug administration on day 3 of period 2</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Period 1: BIBR1048 MS Capsule A+Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: BIBR1048 MS Capsule B+Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: BIBR1048 MS Capsule C+Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: BIBR1048 MS Capsule D+Pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: BIBR1048 MS solution+Pantoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: BIBR1048 MS Capsule C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: BIBR1048 MS Capsule D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: BIBR1048 MS solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule A</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS Capsule A+Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule B</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS Capsule B+Pantoprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule C</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS Capsule C+Pantoprazole</arm_group_label>
    <arm_group_label>Period 2: BIBR1048 MS Capsule C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS Capsule D</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS Capsule D+Pantoprazole</arm_group_label>
    <arm_group_label>Period 2: BIBR1048 MS Capsule D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS tartaric acid solution</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS solution+Pantoprazole</arm_group_label>
    <arm_group_label>Period 2: BIBR1048 MS solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <arm_group_label>Period 1: BIBR1048 MS Capsule A+Pantoprazole</arm_group_label>
    <arm_group_label>Period 1: BIBR1048 MS Capsule B+Pantoprazole</arm_group_label>
    <arm_group_label>Period 1: BIBR1048 MS Capsule C+Pantoprazole</arm_group_label>
    <arm_group_label>Period 1: BIBR1048 MS Capsule D+Pantoprazole</arm_group_label>
    <arm_group_label>Period 1: BIBR1048 MS solution+Pantoprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects as determined by results of screening

          -  Signed written informed consent in accordance with GCP (Good Clinical Practice) and
             local legislation

          -  Age &gt;= 18 and &lt;= 55 years

          -  Body Mass Index (BMI) &gt;= 18.5 and &lt;= 29.9 kg/m²

        Exclusion Criteria:

          -  Any finding at the medical examination (including blood pressure, pulse rate and ECG
             (electrocardiogram)) deviation from normal and of clinical relevance

          -  History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of relevant orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  History of any bleeding disorder including prolonged or habitual bleeding

          -  History of other hematologic disease

          -  History of cerebral bleeding (e.g. after a car accident)

          -  History of commotio cerebri

          -  Intake of drug with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs that might influence the results of the trial within 10 days prior to
             administration or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60g/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range

          -  History of any familial bleeding disorder

          -  Thrombocytes &lt; 150000/µl
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

